Abstract
Background: Previous studies of the efficacy and safety of cetuximab-based regimen do not clearly consider except for a treatment with platinum-based chemotherapy. Objective: The purpose of this study is to consider efficacy and safety of weekly Paclitaxel plus Cetuximab in the first-line treatment of patients with recurrent/metastatic squamous cell carcinoma of head and neck (RM-SCCHN). Results: Between Mar 2013 and Jan 2016, fifty-five pts were treated. The median age was 63 years (range20-82). 50 pts were evaluable for response. The ORR was 50.9%, with 2 (3.6%) complete responses and 26 (47.2%) partial responses. Median PFS and OS were 7.7 months (95% CI 6.3-9.1) and 17 months (95% CI 15-23). Treatment-related severe adverse events were Interstitial pneumonitis (7.2%). Conclusion: It is clinically useful to enforce paclitaxel + cetuximab combination therapy for RM-SCCHN as the primary chemotherapy, but additional research is required for patient's adaptation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
